Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Operating Expenses (2018 - 2025)

Historic Operating Expenses for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $33.7 million.

  • Arcturus Therapeutics Holdings' Operating Expenses fell 3576.99% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $175.9 million, marking a year-over-year decrease of 2697.62%. This contributed to the annual value of $248.0 million for FY2024, which is 121.43% up from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' Operating Expenses stood at $33.7 million, which was down 3576.99% from $39.9 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Operating Expenses ranged from a high of $71.0 million in Q2 2024 and a low of $33.7 million during Q3 2025
  • Moreover, its 5-year median value for Operating Expenses was $55.6 million (2022), whereas its average is $53.8 million.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Operating Expenses skyrocketed by 39383.05% in 2021, and later crashed by 4376.7% in 2025.
  • Arcturus Therapeutics Holdings' Operating Expenses (Quarter) stood at $43.4 million in 2021, then decreased by 10.58% to $38.8 million in 2022, then grew by 26.48% to $49.1 million in 2023, then increased by 14.32% to $56.2 million in 2024, then plummeted by 40.06% to $33.7 million in 2025.
  • Its Operating Expenses stands at $33.7 million for Q3 2025, versus $39.9 million for Q2 2025 and $46.2 million for Q1 2025.